Loading organizations...
§ Public · San Francisco, CA, USA
develops single-use lighted surgical instruments to enhance visualization during minimally invasive procedures in surgical specialties.
Invuity, based in San Francisco, California, developed advanced photonics and single-use lighted surgical instruments to enhance visualization during minimally invasive procedures. Their product portfolio, including retractors, handheld devices, and intracavity illuminators, provided clear anatomical views for surgeons in specialties like orthopedics, spine, general surgery, and women's health. The company raised $25 million in Series D funding, led by Valence Life Sciences, with participation from investors such as Kleiner Perkins Caufield & Byers, InterWest Partners, and Wexford Capital. Invuity was acquired by Stryker in 2018 for approximately $190 million, at $7.40 per share. Philip Sawyer served as CEO during a period that included the commercial launch of their Eigr technology. Founded in 2004. Its business model centers on sold single-use surgical illumination devices and instruments to medical professionals and hospitals, publicly traded prior to acquisition, generating revenue through product sales and partnerships with large medical device companies.
Invuity has raised $119.0M across 5 funding rounds.
Invuity has raised $119.0M in total across 5 funding rounds.
Invuity has raised $119.0M across 5 funding rounds. Most recently, it raised $20.0M Other Equity in February 2015.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 17, 2015 | $20M Venture Round | Wellington Management | Gregory Lucier, Healthcare Royalty Partners, Interwest Partners, Kleiner Perkins, Valence Life Sciences | Announced |
| Mar 4, 2014 | $36M Debt Financing | Greg Brown | Interwest Partners, Kleiner Perkins, Valence Life Sciences | Announced |
| Mar 1, 2014 | $36M Series E | Healthcare Royalty Partners | Amoon Fund, Domain Associates, InterWest, Osage University Partners, Vivo Capital, Kleiner Perkins, Valence Life Sciences | Announced |
| Jun 1, 2012 | $25M Series D | Eric Roberts | Amoon Fund, Domain Associates, InterWest, Osage University Partners, Vivo Capital, Interwest Partners, Kleiner Perkins, Wexford Capital | Announced |
| Jan 1, 2012 | $2M Series U | — | Amoon Fund, Domain Associates, InterWest, Osage University Partners, Vivo Capital | Announced |
Invuity is a medical technology company that develops advanced surgical devices using patented Intelligent Photonics technology to deliver superior intracavity illumination and visualization during minimally invasive procedures.[1][2][3] Its products, such as illuminated retractors and hand-held devices, serve surgeons in specialties including orthopedics, spine, breast and thyroid oncology, plastic surgery, general abdominal, and hip surgery, addressing limitations of traditional operating room lighting by providing thermally cool, uniform light to deep surgical cavities.[1][2][4][5] The company solved critical visualization challenges in open, minimally invasive, and minimal access surgeries, improving precision, reducing thermal risks, and enhancing patient outcomes; it went public but faced operational challenges before being acquired by Stryker in 2018.[2][8]
Founded in 2004 in San Francisco, California, Invuity originated as Spotlight Surgical before rebranding; it pioneered advanced photonics for surgical visualization, initially focusing on hand-held illumination devices and access systems.[1][2][3] The core idea emerged from addressing poor lighting in deep surgical cavities, leading to proprietary optical waveguide technology that shapes brilliant, cool light—initial traction came through patented innovations in fiber optics and surgery, with 124 patents filed.[1][2] Pivotal moments included product expansions into specialties like orthopedics and oncology, marketing animations for devices like the Yankauer and EIGR technology, and its 2018 acquisition by Stryker, marking the end of independent operations.[2][4]
Invuity rode the trend toward minimally invasive surgery (MIS), where improved visualization is essential amid rising demand for procedures that reduce recovery time and complications in aging populations.[1][2][4] Timing aligned with advancements in photonics and optics during the 2000s-2010s, fueled by market forces like electrosurgery growth and limitations of overhead lights in deep cavities.[5][7] Its innovations influenced the medtech ecosystem by setting standards for intracavity lighting—post-acquisition by Stryker in 2018, the technology integrated into larger portfolios, enhancing tools for orthopedics and general surgery while competitors like HydroCision and Advanced Surgical Concepts pursued complementary access tech.[2][5]
Since its 2018 acquisition by Stryker, Invuity operates as an integrated brand under Stryker's Surgical Technologies, with products like the Illuminated Retractor System continuing to evolve for broader MIS adoption.[2][5] Trends like AI-assisted surgery, robotics (e.g., da Vinci systems), and gynecology expansion will shape its path, potentially amplifying light tech in hybrid procedures.[7] Its influence may grow through Stryker's global scale, driving further photonics innovations that tie back to the core mission: transforming dark surgical cavities into brilliantly lit fields for safer, more precise operations.[1][5]
Invuity has raised $119.0M in total across 5 funding rounds.
Invuity's investors include Wellington Management, Gregory Lucier, HealthCare Royalty Partners, InterWest Partners, Kleiner Perkins, Valence Life Sciences, Greg Brown, aMoon Fund, Domain Associates, InterWest, Osage University Partners, Vivo Capital.